Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (581-590 of 1,211) with videos related to

Pageof 122
Sort By:
JAMA|November 9, 2015
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized TrialMihai Gheorghiade, Stephen J Greene, Javed Butler, et al.
Journal of the American Heart Association|March 7, 2025
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic CardiomyopathyBryton J Davis, Hailey Volk, Olives Nguyen, et al.
Journal of the American College of Cardiology|November 15, 2019
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEFMuthiah Vaduganathan, Brian L Claggett, Akshay S Desai, et al.
Circulation|July 20, 2007
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programSatish Kenchaiah, Stuart J Pocock, Duolao Wang, et al.
The Lancet. Diabetes & Endocrinology|March 24, 2017
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trialJelena P Seferovic, Brian Claggett, Sara B Seidelmann, et al.
Circulation. Heart Failure|March 21, 2023
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF TrialJawad H Butt, Wasyla Ibrahim, Pooja Dewan, et al.
European Journal of Heart Failure|April 8, 2024
Effects of sacubitril/valsartan according to polypharmacy status in PARAGON-HFShingo Matsumoto, Mingming Yang, Li Shen, et al.
JACC. Heart Failure|November 30, 2024
Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional OutcomesEperke Merkel, Robert Hatala, Mátyás Szigeti, et al.
European Journal of Heart Failure|June 7, 2017
Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) studyGerasimos Filippatos, Aldo P Maggioni, Carolyn S P Lam, et al.
European Journal of Heart Failure|October 28, 2022
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
Pageof 122

Showing results (581-590 of 1,211) with videos related to

Sort By:
Pageof 122
JAMA|November 9, 2015
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized TrialMihai Gheorghiade, Stephen J Greene, Javed Butler, et al.
Journal of the American Heart Association|March 7, 2025
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic CardiomyopathyBryton J Davis, Hailey Volk, Olives Nguyen, et al.
Journal of the American College of Cardiology|November 15, 2019
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEFMuthiah Vaduganathan, Brian L Claggett, Akshay S Desai, et al.
Circulation|July 20, 2007
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programSatish Kenchaiah, Stuart J Pocock, Duolao Wang, et al.
The Lancet. Diabetes & Endocrinology|March 24, 2017
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trialJelena P Seferovic, Brian Claggett, Sara B Seidelmann, et al.
Circulation. Heart Failure|March 21, 2023
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF TrialJawad H Butt, Wasyla Ibrahim, Pooja Dewan, et al.
European Journal of Heart Failure|April 8, 2024
Effects of sacubitril/valsartan according to polypharmacy status in PARAGON-HFShingo Matsumoto, Mingming Yang, Li Shen, et al.
JACC. Heart Failure|November 30, 2024
Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional OutcomesEperke Merkel, Robert Hatala, Mátyás Szigeti, et al.
European Journal of Heart Failure|June 7, 2017
Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) studyGerasimos Filippatos, Aldo P Maggioni, Carolyn S P Lam, et al.
European Journal of Heart Failure|October 28, 2022
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
Pageof 122